PCM
NBIX icon

Prelude Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Prelude Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-5,500
Closed -$253K – 1813
2017
Q2 		$253K Sell
5,500
-2,000
-27% -$97K 0.02% 510
2017
Q1 		$325K Buy
7,500
+5,500
+275% +$236K 0.03% 417
2016
Q4 		$77K Buy
2,000
+1,000
+100% +$45.3K 0.01% 906
2016
Q3 		$51K Buy
+1,000
New +$49.8K 0.01% 1035
2015
Q4 		– Sell
-500
Closed -$20K – 1611
2015
Q3 		$20K Buy
+500
New +$24.2K ﹤0.01% 1248
2015
Q2 		– Sell
-500
Closed -$20K – 1925
2015
Q1 		$20K Sell
500
-8,100
-94% -$290K ﹤0.01% 1746
2014
Q4 		$192K Sell
8,600
-3,700
-30% -$70.1K 0.03% 660
2014
Q3 		$193K Sell
12,300
-2,400
-16% -$35.9K 0.03% 728
2014
Q2 		$218K Buy
+14,700
New +$207K 0.03% 707
2014
Q1 		– Sell
-1,900
Closed -$18K – 2026
2013
Q4 		$18K Sell
1,900
-4,700
-71% -$45.9K ﹤0.01% 1357
2013
Q3 		$75K Buy
+6,600
New +$90.7K 0.01% 865

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Prelude Capital Management's NBIX Position: Q1 2026 in Review

Prelude Capital Management sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 1,808 shares — an estimated $256K sold.

Prelude Capital Management first reported a position in NBIX in Q3 2013 and held it in 26 quarters. The position peaked at $2.65M in Q3 2017. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Prelude Capital Management reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
  • Prelude Capital Management sold 1,808 Neurocrine Biosciences shares in Q1 2026, an estimated $256K.
  • Prelude Capital Management first reported a position in Neurocrine Biosciences in Q3 2013 and held it in 26 quarters.
  • Prelude Capital Management's Neurocrine Biosciences position peaked at $2.65M in Q3 2017.
  • 695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.